Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have transformed the treatment landscape in front-line and recurrent high-grade serous ovarian cancer. Maintenance strategies with PARPi have been assessed in randomized phase III trials in ovarian cancer; switch maintenance in the case of olapa...

Descripción completa

Detalles Bibliográficos
Autores principales: Madariaga, Ainhoa, Bowering, Valerie, Ahrari, Soha, Oza, Amit M, Lheureux, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398227/
https://www.ncbi.nlm.nih.gov/pubmed/32276934
http://dx.doi.org/10.1136/ijgc-2020-001288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398227/
https://www.ncbi.nlm.nih.gov/pubmed/32276934
http://dx.doi.org/10.1136/ijgc-2020-001288

Ejemplares similares